[go: up one dir, main page]

IN2014DN09618A - - Google Patents

Info

Publication number
IN2014DN09618A
IN2014DN09618A IN9618DEN2014A IN2014DN09618A IN 2014DN09618 A IN2014DN09618 A IN 2014DN09618A IN 9618DEN2014 A IN9618DEN2014 A IN 9618DEN2014A IN 2014DN09618 A IN2014DN09618 A IN 2014DN09618A
Authority
IN
India
Prior art keywords
fusion protein
plasmid
expression
fused
generation
Prior art date
Application number
Inventor
Dennis J Kopecko
Manuel Osorio
Monica R Foote
Original Assignee
Us Sec Dep Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Sec Dep Of Health And Human Services filed Critical Us Sec Dep Of Health And Human Services
Publication of IN2014DN09618A publication Critical patent/IN2014DN09618A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0291—Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Described herein is the generation of a plasmid construct for expression of a Fl- V fusion protein. In the disclosed plasmid , the F1- V fusion protein coding sequence is operably linked to the htrA promoter , and is fused in frame to the HlyA secretion signal sequence. Also described is serovar Typhi strain Ty21a containing the F1- V fusion protein expression plasmid , such as for use as an oral vaccine against plague.
IN9618DEN2014 2012-05-23 2013-05-22 IN2014DN09618A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261650676P 2012-05-23 2012-05-23
PCT/US2013/042240 WO2013177291A1 (en) 2012-05-23 2013-05-22 Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof

Publications (1)

Publication Number Publication Date
IN2014DN09618A true IN2014DN09618A (en) 2015-07-31

Family

ID=48539444

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9618DEN2014 IN2014DN09618A (en) 2012-05-23 2013-05-22

Country Status (7)

Country Link
US (1) US9409956B2 (en)
EP (1) EP2852405B1 (en)
JP (1) JP6216371B2 (en)
CN (1) CN104470537B (en)
IL (1) IL235615A0 (en)
IN (1) IN2014DN09618A (en)
WO (1) WO2013177291A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806778B2 (en) * 2019-01-30 2020-10-20 Prokarium Limited Modified strain of Salmonella enterica Typhi

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856935A (en) 1971-04-29 1974-12-24 Schweiz Serum & Impfinst Oral typhoid vaccine and method of preparing the same
GB9326425D0 (en) 1993-12-24 1994-02-23 Secr Defence Vaccine compositions
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2215203C (en) * 1995-03-13 2008-12-09 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Vaccines for plague
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING NON-METHYLIC CpG DINUCLEOTIDES IN THE TREATMENT OF LIPOPOLYSACCHARIDE ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
DE69939264D1 (en) * 1998-09-04 2008-09-18 Emergent Product Dev Uk Ltd ATTENUATED SALMONELLA SPI2 MUTANTE AS ANTIGEN CARRIER
GB9921275D0 (en) * 1999-09-10 1999-11-10 Secr Defence Recombinant microorganisms
WO2005026203A2 (en) 2003-09-18 2005-03-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna promoters and anthrax vaccines
EP1691615A2 (en) * 2003-12-09 2006-08-23 Avant Immunotherapeutics, Inc. Orally-administered live bacterial vaccines for plague
US20080124355A1 (en) * 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof

Also Published As

Publication number Publication date
WO2013177291A1 (en) 2013-11-28
US20150152144A1 (en) 2015-06-04
US9409956B2 (en) 2016-08-09
CN104470537A (en) 2015-03-25
WO2013177291A8 (en) 2014-12-24
JP2015519061A (en) 2015-07-09
IL235615A0 (en) 2015-01-29
EP2852405A1 (en) 2015-04-01
EP2852405B1 (en) 2019-03-13
JP6216371B2 (en) 2017-10-18
CN104470537B (en) 2017-04-26

Similar Documents

Publication Publication Date Title
MY186535A (en) Novel european prrsv strain
MX2015005797A (en) Production of recombinant vaccine in e. coli by enzymatic conjugation.
PH12013502121A1 (en) Fusion proteins and combiantion vaccines comprising haemophilus influenzae preotein e and pilin a
NZ602278A (en) Bluetongue virus recombinant vaccines and uses thereof
EA201391183A1 (en) METHODS OF STRENGTHENING IMMUNOGENSPECIFIC IMMUNE RESPONSES WITH THE HELP OF VECTOR VECTIONS
WO2013106510A3 (en) Clostridium histolyticum enzymes and methods for the use thereof
MX2010001284A (en) Multimeric multiepitope influenza vaccines.
MX2010012999A (en) Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof.
SG10201700916SA (en) Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
IN2015DN02771A (en)
NZ703701A (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
MX2013003470A (en) Consensus antigen constructs and vaccines made therefrom, and methods of using same to treat malaria.
MX2016007939A (en) Novel msln targeting dna vaccine for cancer immunotherapy.
MX2017015404A (en) Surface display of antigens on gram-negative outer membrane vesicles.
IL236663A0 (en) Generation of native recombinant secreted human endoplasmic reticulum chaperones by using their native signal sequences in yeast expression systems
EP3978013A3 (en) A novel live attenuated shigella vaccine
MD4481B1 (en) Recombinant Koi herpesvirus (KHV) and vaccine for the prevention of a disease caused by KHV
NZ596501A (en) Casb7439 constructs
GB201017519D0 (en) Vaccines
WO2011067758A3 (en) Immunogenic fragments and multimers from streptococcus pneumoniae proteins
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
DK201370530A (en) Salmonid alphavirus vaccine
MX350460B (en) Mouth rinses and tooth sensitivity treatment compositions.
NZ589981A (en) Cattle vaccines comprising a disrupted M. bovis bacterium
IN2014DN09618A (en)